Acipimox

CLINICAL USE

Hyperlipidaemia

DOSE IN NORMAL RENAL FUNCTION

250 mg 2 or 3 times daily

PHARMACOKINETICS

  • Molecular weight                           :
    154.1
  • %Protein binding                           :
    0
  • %Excreted unchanged in urine     :
    86–90
  • Volume of distribution (L/kg)       :
    0.3–0.4
  • half-life – normal/ESRD (hrs)      :
    2/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    40–80 250 mg daily
    20–40 250 mg alternate days.
    <20
    See ‘Other Information’

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :
    Likely dialysability. Dose as in
    GFR<20 mL/min
  • HD                     :
    Dialysed. Dose as in
    GFR<20 mL/min
  • HDF/high flux   :
    Dialysed. Dose as in
    GFR<20 mL/min
  • CAV/VVHD      :
    Dialysed. Dose as in
    GFR=20–40 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    Take with or after meals

    OTHER INFORMATION

  • Females are twice as likely as males tosuffer from side effects, e.g. flushing,
    pruritus and skin rashes
  • Doses up to 1200 mg have been givensafely for long periods
    After a 5 hour dialysis 70% of the drug had

    been removed

  • Dollery advises the doses given in thetable, down to 20 mL/minute, but nothing
    after that.
    Micromedex gives the following

    recommendations:
    GFR: 30–60 mL/min 150 mg twice daily
    GFR: 10–30 mL/min 150 mg once daily
    GFR:

  • <10           : mL/min 150 mg alternate days
    • Tags:

    Related News

    ffddfd

    Hyperlipidemia